Everolimus in the treatment of hormone receptor-positive breast cancer

By Chavez-MacGregor Mariana   Gonzalez-Angulo Ana Maria  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 12, 2012-12 ,pp. : 1835-1843

Informa Healthcare

Access to resources Recommend Favorite

Active smoking and the risk of estrogen receptor-positive and triple-negative breast cancer among women ages 20 to 44 years

By Kawai Masaaki   Malone Kathleen E.   Tang Mei-Tzu C.   Li Christopher I.  

Cancer, Vol. 120, Iss. 7, 2014-04 ,pp. : 1026-1034

Blackwell Publishing

Access to resources Recommend Favorite

Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer

By Montemurro Filippo   Rossi Valentina   Geuna Elena   Valabrega Giorgio   Martinello Rossella   Milani Andrea   Aglietta Massimo  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 15, 2012-10 ,pp. : 2143-2156

Informa Healthcare

Access to resources Recommend Favorite

The Aromatase Inhibitors as Adjuvant Therapy for Hormone Receptor-Positive Breast Cancer

By Ligibel Jennifer A.   Winer Eric P.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 1, Iss. 2, 2003-04 ,pp. : 215-221

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Height, body mass index (BMI), BMI change, and the risk of estrogen receptor-positive, HER2-positive, and triple-negative breast cancer among women ages 20 to 44 years

By Kawai Masaaki   Malone Kathleen E.   Tang Mei-Tzu C.   Li Christopher I.  

Cancer, Vol. 120, Iss. 10, 2014-05 ,pp. : 1548-1556

Blackwell Publishing

Access to resources Recommend Favorite